Impaired intracellular trafficking defines early Parkinson's disease

Trends in Neurosciences

Volumn 38, Issue 3, 2015, Pages 178-188

  Hunn, Benjamin H M ^a   Cragg, Stephanie J ^a   Bolam, J Paul ^a   Spillantini, Maria Grazia ^b   Wade Martins, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cell trafficking; Parkinson's disease; Tau; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CARRIER PROTEIN; SNARE PROTEIN; TAU PROTEIN;

CELL LOSS; CHROMOSOME 17; DISEASE MODEL; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; GENE MUTATION; GOLGI COMPLEX; HUMAN; INTRACELLULAR TRANSPORT; LEWY BODY; NEURITE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM; NERVE CELL; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; NEURONS; PARKINSON DISEASE;

EID: 84924625546     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2014.12.009     Document Type: Review

References (120)

1. Lees A.J., et al. Parkinson's disease. Lancet 2009, 373:2055-2066.
2. de Rijk M.C., et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology 1995, 45:2143-2146.
3. Dorsey E.R., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
4. Dodel R.C., et al. The economic impact of Parkinson's disease. PharmacoEconomics 1998, 14:299-312.
5. Findley L., et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov. Disord. 2003, 18:1139-1145.
6. Kowal S.L., et al. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 2013, 28:311-318.
7. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
8. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30:194-202.
9. Moss J., Bolam J.P. A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. J. Neurosci. 2008, 28:11221-11230.
10. Braak H., Del Tredici K. Neuroanatomy and Pathology of Sporadic Parkinson's Disease 2008, Springer Science & Business Media.
11. Bolam J.P., Pissadaki E.K. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov. Disord. 2012, 27:1478-1483.
12. Moss J., Bolam J.P. The relationship between dopaminergic axons and glutamatergic synapses in the striatum: structural considerations. Dopamine Handbook 2010, 49-59. Oxford University Press. L.L. Iversen (Ed.).
13. Matsuda W., et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 2009, 29:444-453.
14. Hancock W.O. Bidirectional cargo transport: moving beyond tug of war. Nat. Rev. Mol. Cell Biol. 2014, 15:615-628.
15. Hua W., et al. Coupling of kinesin steps to ATP hydrolysis. Nature 1997, 388:390-393.
16. Pissadaki E.K., Bolam J.P. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci. 2013, 7:13.
17. Guzman J.N., et al. Robust pacemaking in substantia nigra Dopaminergic neurons. J. Neurosci. 2009, 29:11011-11019.
18. Xu J., et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8:600-606.
19. Nalls M.A., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 2014, 46:989-993.
20. Singleton A.B., et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
21. Ibáñez P., et al. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1169-1171.
22. Chandra S., et al. α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell 2005, 123:383-396.
23. Senior S.L., et al. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci. 2008, 27:947-957.
24. Anwar S., et al. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J. Neurosci. 2011, 31:7264-7274.
25. Rozas J.L., et al. Motorneurons require cysteine string protein-α to maintain the readily releasable vesicular pool and synaptic vesicle recycling. Neuron 2012, 74:151-165.
26. Madeo F., et al. Can autophagy promote longevity?. Nat. Cell Biol. 2010, 12:842-846.
27. Mata I.F., et al. SNCA variant associated with Parkinson disease and plasma α-synuclein level. Arch. Neurol. 2010, 67:1350-1356.
28. Fuchs J., et al. Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain. FASEB J. 2008, 22:1327-1334.
29. Greenbaum E.A., et al. The E46K mutation in α-synuclein increases amyloid fibril formation. J. Biol. Chem. 2005, 280:7800-7807.
30. Tokuda T., et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
31. Winner B., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4194-4199.
32. Giehm L., et al. Low-resolution structure of a vesicle disrupting alpha-synuclein oligomer that accumulates during fibrillation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3246-3251.
33. Rockenstein E., et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014, 137:1496-1513.
34. Janezic S., et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4016-E4025.
35. Nemani V.M., et al. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
36. Scott D., Roy S. α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J. Neurosci. 2012, 32:10129-10135.
37. Lundblad M., et al. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3213-3219.
38. Taylor T.N., et al. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse. Neurobiol. Dis. 2014, 62:193-207.
39. Platt N.J., et al. Striatal dopamine transmission is subtly modified in human A53T α-synuclein overexpressing mice. PLoS ONE 2012, 7:e36397.
40. Garcia-Reitböck P., et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 2010, 133:2032-2044.
41. DeWitt D.C., Rhoades E. α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers. Biochemistry 2013, 52:2385-2387.
42. Spinelli K.J., et al. Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. J. Neurosci. 2014, 34:2037-2050.
43. Wilhelm B.G., et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 2014, 344:1023-1028.
44. Soldner F., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
45. Hartfield E.M., et al. Physiological characterisation of human iPS-derived dopaminergic neurons. PLoS ONE 2014, 9:e87388.
46. Tardiff D.F., et al. Yeast reveal a 'druggable' Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science 2013, 342:979-983.
47. Chung C.Y., et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 2013, 342:983-987.
48. Cooper A.A. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
49. Ryan S.D., et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α Transcription. Cell 2013, 155:1351-1364.
50. Gitler A.D., et al. The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:145-150.
51. Tofaris G.K., et al. Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17004-17009.
52. Thayanidhi N., et al. α-Synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 2010, 21:1850-1863.
53. Decressac M., et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E1817-E1826.
54. Nair U., et al. SNARE proteins are required for macroautophagy. Cell 2011, 146:290-302.
55. Lill C.M., et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 2012, 8:e1002548.
56. Stefansson H., et al. A common inversion under selection in Europeans. Nat. Genet. 2005, 37:129-137.
57. Charlesworth G., et al. Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiol. Aging 2012, 33. 838.e7-11.
58. Caffrey T.M., Wade-Martins R. Functional MAPT haplotypes: bridging the gap between genotype and neuropathology. Neurobiol. Dis. 2007, 27:1-10.
59. Vivona S., et al. Disassembly of all SNARE complexes by N-ethylmaleimide-sensitive Factor (NSF) is initiated by a conserved 1:1 interaction between alpha-soluble NSF attachment protein (SNAP) and SNARE complex. J. Biol. Chem. 2013, 288:24984-24991.
60. Wade-Martins R. The MAPT locus - a genetic paradigm in disease susceptibility. Nat. Rev. Neurol. 2012, 8:477-478.
61. Caffrey T.M., et al. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum. Mol. Genet. 2006, 15:3529-3537.
62. Myers A.J., et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol. Dis. 2007, 25:561-570.
63. Trabzuni D., et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum. Mol. Genet. 2012, 21:4094-4103.
64. Majounie E., et al. Variation in tau isoform expression in different brain regions and disease states. Neurobiol. Aging 2013, 34:1922.e7-1922.e12.
65. Zhong Q., et al. Tau isoform composition influences rate and extent of filament formation. J. Biol. Chem. 2012, 287:20711-20719.
66. Brimblecombe K.R., et al. Gating of dopamine transmission by calcium and axonal N, Q, T and L-type voltage-gated calcium channels differs between striatal domains. J. Physiol. 2015, Published online 22 December 2024. http://dx.doi.org/10.1113/jphysiol.2014.285890.
67. Chu Y., et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135:2058-2073.
68. Dixit R., et al. Differential regulation of dynein and kinesin motor proteins by tau. Science 2008, 319:1086-1089.
69. Magnani E., et al. Interaction of tau protein with the dynactin complex. EMBO J. 2007, 26:4546-4554.
70. Maday S., et al. Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J. Cell Biol. 2012, 196:407-417.
71. Farrer M.J., et al. DCTN1 mutations in Perry syndrome. Nat. Genet. 2009, 41:163-165.
72. Roy B., Jackson G.R. Interactions between tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum. Mol. Genet. 2014, 23:3008-3023.
73. Healy D.G., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
74. Piccoli G., et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 2011, 31:2225-2237.
75. Matta S., et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
76. Melrose H.L., et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
77. Kett L.R., et al. LRRK2 Parkinson disease mutations enhance its microtubule association. Hum. Mol. Genet. 2012, 21:890-899.
78. Beilina A., et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:2626-2631.
79. MacLeod D.A., et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 2013, 77:425-439.
80. Alegre-Abarrategui J., et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
81. Weihofen A., et al. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009, 48:2045-2052.
82. Koyano F., et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 2014, 510:162-166.
83. Anheim M., et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012, 78:417-420.
84. Sidransky E., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661.
85. Murphy K.E., et al. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 2014, 137:834-848.
86. Mazzulli J.R., et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
87. Zimprich A., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 2011, 89:168-175.
88. Vilariño-Güell C., et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 2011, 89:162-167.
89. Zavodszky E., et al. Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy. Nat. Commun. 2014, 5:3828.
90. Tsika E., et al. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum. Mol. Genet. 2014, 23:4621-4638.
91. Quadri M., et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum. Mutat. 2013, 34:1208-1215.
92. Krebs C.E., et al. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum. Mutat. 2013, 34:1200-1207.
93. Edvardson S., et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS ONE 2012, 7:e36458.
94. Köroğlu C., et al. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat. Disord. 2013, 19:320-324.
95. Mani M., et al. The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals. Neuron 2007, 56:1004-1018.
96. Braak H., et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 2006, 21:2042-2051.
97. Li J-Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
98. Kordower J.H., et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
99. Kordower J.H., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 1995, 332:1118-1124.
100. Luk K.C., et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
101. Hansen C., et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
102. Desplats P., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13010-13015.
103. Lee H.J. Intravesicular localization and exocytosis of alpha-synuclein and its Aggregates. J. Neurosci. 2005, 25:6016-6024.
104. Emmanouilidou E., et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30:6838-6851.
105. Danzer K.M., et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 2012, 7:42.
106. Tsunemi T., et al. ATP13A2/PARK9 regulates secretion of exosomes and α-Synuclein. J. Neurosci. 2014, 34:15281-15287.
107. Sarkar S., et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 2007, 3:331-338.
108. Masliah E., et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 2011, 6:e19338.
109. Cooper J.M., et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 2014, 29:1476-1485.
110. Lewy F. Paralysis agitans. I. Pathologische Anatomie. Handbuch der Neurologie 1912, Vol. 3:920-933. Springer-Verlag.
111. Bartels T., et al. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
112. Burré J., et al. Properties of native brain α-synuclein. Nature 2013, 498:E4-E6.
113. Fauvet B., et al. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 2012, 287:15345-15364.
114. Dettmer U., et al. In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J. Biol. Chem. 2013, 288:6371-6385.
115. Rao J.N., et al. A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. J. Am. Chem. Soc. 2010, 132:8657-8668.
116. Samaranch L., et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010, 133:1128-1142.
117. Thomas K.J., et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet. 2011, 20:40-50.
118. Ramirez A., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191.
119. Morgan N.V., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 2006, 38:752-754.
120. Larsen K., Bendixen C. Characterization of the porcine FBX07 gene: the first step towards generation of a pig model for Parkinsonian pyramidal syndrome. Mol. Biol. Rep. 2012, 39:1517-1526.